When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report ; volume:12 ; number:1 ; day:20 ; month:3 ; year:2018 ; pages:1-5 ; date:12.2018
Journal of medical case reports ; 12, Heft 1 (20.3.2018), 1-5, 12.2018
- Creator
-
Sbitti, Yassir
- Contributor
-
Debbagh, Adil
Slimani, Khaoula
Mahi, Mohamed
Errihani, Hassan
Ichou, Mohamed
SpringerLink (Online service)
- DOI
-
10.1186/s13256-018-1597-z
- URN
-
urn:nbn:de:1111-2018052021881
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sbitti, Yassir
- Debbagh, Adil
- Slimani, Khaoula
- Mahi, Mohamed
- Errihani, Hassan
- Ichou, Mohamed
- SpringerLink (Online service)
Other Objects (12)
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis
Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
Editorial: Targeting bruton tyrosine kinase
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Surgery for metastatic tumors of the pancreas
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Neurogenin 3 is regulated by neurotrophic tyrosine kinase receptor type 2 (TRKB) signaling in the adult human exocrine pancreas
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis
Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
Editorial: Targeting bruton tyrosine kinase
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Surgery for metastatic tumors of the pancreas
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Neurogenin 3 is regulated by neurotrophic tyrosine kinase receptor type 2 (TRKB) signaling in the adult human exocrine pancreas
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis
Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
Editorial: Targeting bruton tyrosine kinase
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Surgery for metastatic tumors of the pancreas
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML